Key clinical point: Clinical trials, personalized medicine may need to be adjusted for primary tumor location.
Major finding: There was no difference in survival for KRAS mutant versus wild type in liver metastases with rectal origin.
Study details: A retrospective analysis (n = 1,304).
Disclosures: The funding source was not disclosed. The authors had no relevant financial disclosures.
Amini N et al. J Am Coll Surg. 2019 Oct;229(4):Suppl 1, S69-70.